What are the nursing implications when using paliperidone prolonged release for people with schizophrenia

Journal of Psychiatric and Mental Health Nursing

Volumn 15, Issue 10, 2008, Pages 792-799

  Jones, A ^a  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Medication; Mental health; Nurse prescribing

Indexed keywords

9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; DOPAMINE RECEPTOR; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

DECISION MAKING; DELAYED RELEASE FORMULATION; DRUG EFFECT; HUMAN; MICROCAPSULE; MOOD DISORDER; NURSING; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CAPSULES; DECISION MAKING; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; MOOD DISORDERS; PYRIMIDINES; RECEPTORS, DOPAMINE; SCHIZOPHRENIA;

EID: 55349101633     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2008.01299.x     Document Type: Review

References (47)

1. Arakawa R., Ito H., Takano A., et al. (2008) Psychopharmacology 197, 229 235.
2. Bernard S., Neville K.A., Ngujen A., et al. (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 11, 126 135.
3. Brown S., Birtwistle S., Birtwistle J., et al. (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 29, 697 701.
4. Canuso C., Dirks B., Carothers J., et al. (2007) A double-blind, placebo-controlled trial of paliperidone and quetiapine in patients with a recent acute exacerbation of schizophrenia. Poster presented at the 20th Annual US Psychiatric & Mental Health Congress, October 11-14, 2007. Orlando, Florida.
5. Chemerinski E., Ho B.C., Flaum M., et al. (2002) Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Comprehensive Psychiatry 43, 393 396.
6. Citrome L. (2007) Paliperidone: quo vadis? International Journal of Clinical Practice 61, 653 662.
7. Collis I. Lloyd G. (1992) Psychiatric aspects of liver disease. British Journal of Psychiatry 161, 12 22.
8. Conley R. (2006) Review of the clinical spectrum of the osmotic-controlled release oral delivery system (OROS) and application in central nervous system disorders. Poster Presented at CINP 9-13th July, 2006, Chicago, IL, USA.
9. Coyle J.T. (2006) Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotoxicology Research 10, 221 233.
10. Davidson M., Emsley R., Kramer M., et al 2007) Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomised, placebo-controlled study. Schizophrenia Research 81 (Suppl. 1 43.
11. DH (2006a) Medicines Matters. A Guide to Mechanisms for the Prescribing, Supply and Administration of Medicines. DH, London.
12. DH (2006b) Improving Patients' Access to Medicines: A Guide to Implementing Nurse and Pharmacist Independent Prescribing within the NHS in England. DH, London.
13. Dollery C. (1999) Therapeutic Drugs, 2nd edn. Churchill Livingstone, Edinburgh.
14. Duggal H.S. (2007) Possible neuroleptic malignant syndrome associated with paliperidone. Journal Neuropsychiatry Clinical Neurosciences 19, 477 478.
15. Eerdekens M., Kramer M., Rossenu S., et al 2006) Effect of paliperidone extended-release tablets on prolactin exposure in patients with stable schizophrenia. Poster presented at USP and MHC 2006, 16-19 November 2006, New Orleans, USA.
16. Eerdekens M., Kramer M., Lane R., et al 2007) Efficacy and tolerability of oral paliperidone extended release tablets in the treatment of acute schizophrenia: pooled data from three 52-week, open-label extension studies. Poster Presented at ICOSR 28 March-1 April 2007, Colorado, USA.
17. Ewusi-Mensah I., Saunders J.B., Wodak A.D., et al. (1983) Psychiatric morbidity in patients with alcoholic liver disease. British Medical Journal 287, 1417 1419.
18. Graham H.L., Maslin J., Copello A., et al. (2001) Drug and alcohol problems amongst individuals with severe mental health problems in an inner city area of the UK. Social Psychiatry & Psychiatric Epidemiology 36, 448 455.
19. Guest J.F. Cookson R.F. (1999) Cost of schizophrenia to UK society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 15, 597 610.
20. Jones A. (2006) Acute psychiatric inpatient wards. Nurse Prescriber, 1 5. doi:1017/S1467115806000010.
21. Jones A. (2008) Exploring independent nurse prescribing for mental health settings. Journal of Psychiatric & Mental Health Nursing 15, 109 117.
22. Jones A. Jones M. (2005) Mental health nurse prescribing: issues for the UK. Journal of Psychiatric & Mental Health Nursing 12, 527 535.
23. Jones M. Jones A. (2008) Choice as an intervention to promote well-being: the role of the nurse prescriber. Journal of Psychiatric & Mental Health Nursing 15, 75 81.
24. Jones P.B., Barnes T.R.E., Davies L., et al 2006) Randomised controlled trial of the effect on quality of life of second vs. first generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia (CUtLASS 1). Archives General Psychiatry 63, 1079 1087.
25. Kane J., Canas F., Kramer M., et al. (2007) Treatment of schizophrenia with paliperidone extended release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 90, 147 161.
26. Karlsson P., Dencker E., Mannaert E., et al. (2006) Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophrenia Research 81, 85 86.
27. Kramer M., Simpson G., Maciulis V., et al. (2007) Paliperidone extended release tablets for the prevention of symptom recurrence in patients with schizophrenia: a randomised, double blind, placebo-controlled study. Journal of Clinical Psychopharmacology 27, 15 21.
28. Leipzig R.M. (1990) Psychopharmacology in patients with hepatic and gastrointestinal disease. International Journal of Psychiatry in Medicine 20, 109 139.
29. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209 1223.
30. Luthringer R., Staner L., Noel N., et al. (2006) Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets. Neuropsychopharmacology 16, S224.
31. Luthringer R., Luc S., Noel N., et al. (2007) A double-blind, placebo-controlled, randomised study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. International Clinical Psychopharmacology 22, 299 308.
32. Marder S.R., Kramer M., Ford L., et al. (2006) Efficacy and tolerability of two fixed dosages of paliperidone extended release tablets in the treatment of acute schizophrenia: a 6-week placebo-controlled study. Schizophrenia Research 81, 56.
33. Meltzer H., Kramer M. Gassmann-Mayer C. (2006) Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studies. International Journal of Neuropsychopharmacology 9 (Suppl. 1 S225 6.
34. Menezes P.O., Johnson S., Thornicroft G., et al. (1996) Drug and alcohol problems among individuals with severe mental illness in South London. British Journal of Psychiatry 168, 612 619.
35. National Prescribing Centre (2005) Improving Mental Health Services by Extending the Role of Nurses in Prescribing and Supplying Medication: Good Practice Guide. HMSO, London.
36. Newcomer J.W. Haupt D.W. (2006) The metabolic effects of antipsychotic medications. Canadian Journal of Psychiatry 51, 480 91.
37. NICE (2003) Schizophrenia: Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. NICE, London.
38. Norman I.J., While A., Whittlesea C., et al. (2007) Evaluation of Mental Health Nurse Supplementary Prescribing: Final Report to the Department of Health (England). King's College, London.
39. Peuskens J. Group R.S. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry 166, 712 716.
40. Rosenberg S.D., Goodman L.A., Osher F.C., et al. (2001) Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health 91, 27 33.
41. Seeman P. (2005) An update of fast-off dopamine D2 atypical antipsychotics. American Journal of Psychiatry 162, 1984 85.
42. Stahl S.M. (2006) Essential Psychopharmacology. Cambridge University Press, Cambridge.
43. Taylor D., Paton C. Kerwin R. (2005) 2005-2006 Prescribing Guidelines. Taylor & Francis, London.
44. Thyssen A., Crauwels H. Cleton A. (2006) Effects of Hepatic Impairment on the Pharmacokinetics of Immediate-Release Paliperidone. 46th Annual Meeting New Clinical Drug Evaluation Unit, Boca Raton. Session 1-90, Abstract 186.
45. Tzimos A., Kramer M. Ford L. (2006) A 6-week placebo controlled study on the safety and tolerability of flexible doses of oral paliperidone extended release tablets in the treatment of schizophrenia in elderly patients. Poster presented at the CINP 9-13 July, 2006, Chicago, IL, USA.
46. Vermeir M., Boom S., Naessens I., et al. (2006) Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. European Neuropsychopharmacology 15 (Suppl. 3 S648.
47. Zaleon C.R. Guthrie S.K. (1994) Antipsychotic drug use in older adults. American Journal of Hospital Pharmacy 51, 2917 2943.